Biogen Inc (MEX:BIIB) Stock Price, Trades & News
This article provides a detailed stock summary page for Biogen Inc (MEX:BIIB), covering its current stock price, key financial metrics like P/E ratio, market cap, and enterprise value. It also includes an overview of the company's business description as a biopharmaceutical firm focused on neurodegenerative and rare diseases, along with various financial strength, growth, profitability, and valuation ranks. The page highlights warning signs detected by GuruFocus and lists upcoming stock events and recent press releases related to the company.
Pfizer Trades at Just 8.5x Earnings While Peers Fetch 16x. Is the Discount Justified?
Pfizer is currently trading at a significantly lower earnings multiple (8.5x) compared to its pharmaceutical peers (16.4x), raising questions about whether this discount is justified. The market is weighing Pfizer's pipeline challenges, such as a failed oncology trial, against its strong dividend, rebuilt commercial infrastructure, and future growth projections for 2029 and beyond. The article suggests that proof of pipeline success and reaffirmation of guidance are necessary to validate the company's long-term growth story and reduce the current valuation gap.
Roche pens $490m Astex breast cancer license deal
Roche's subsidiary, Genentech, has signed a global drug discovery and licensing deal with UK biotech Astex Pharmaceuticals for breast cancer drugs. Roche will provide $25 million upfront and potential payments exceeding $465 million based on milestones, along with tiered royalties. This collaboration aims to identify new preclinical candidates for breast cancer treatment, with Genentech leading development and commercialization. The deal highlights Roche's continuing investment in oncology and the growing presence of the UK life sciences sector.
Beam Therapeutics stock hits 52-week high at 36.89 USD
Beam Therapeutics Inc. (BEAM) stock has surged to a new 52-week high of $36.89, currently trading at $37.02, reflecting a 90.88% increase over the past year. This growth is attributed to investor confidence in its genetic medicine approaches and recent positive developments, including FDA clearance for BEAM-304 and promising clinical data from BEAM-302 and BEACON trials. Analysts like H.C. Wainwright have reiterated a "Buy" rating with an $80.00 price target, highlighting the company's progress and strategic initiatives.
Astex Announces Exclusive Research Collaboration and License Agreement with Genentech for Breast Cancer Therapy Program
Astex Pharmaceuticals has announced an exclusive worldwide research collaboration and license agreement with Genentech, a member of the Roche Group, to discover small molecule drug candidates for breast cancer therapy. The collaboration leverages Astex’s fragment-based drug discovery expertise and targets a key cell-cycle-dependent regulator. Astex will receive an upfront payment of $25 million and is eligible for over $490 million in milestone payments, plus tiered royalties on net sales.
Novartis to Buy Cancer-Drug Firm Myricx for Up to $1.5 Billion
Novartis AG has agreed to acquire British biotech Myricx Bio for up to $1.5 billion. This acquisition aims to bolster Novartis's cancer drug portfolio with Myricx's experimental therapies that target tumors specifically, minimizing harm to healthy cells. Myricx shareholders are set to receive $1.1 billion upfront, with an additional $400 million in potential milestone payments.
5 molecular glues that could stick—and the companies stuck in
Molecular glue degraders are gaining significant traction in drug development for treating "undruggable" cancers and immunological diseases, attracting substantial funding and partnerships from major pharmaceutical companies. This article highlights five clinical programs from Bristol Myers Squibb, Monte Rosa Therapeutics, C4 Therapeutics, Neomorph, and Degron Therapeutics, showcasing their innovative approaches and the potential for these molecules to revolutionize treatment options. The use of AI in discovering novel targets is accelerating this field, creating new therapeutic avenues.
Merck & Co. outlook and strategy. A closer look at the pharma giant
This article provides an in-depth overview of Merck & Co., a major global pharmaceutical company. It details Merck's business model, strategic focus on oncology and vaccines, financial profile, and research and development pipeline. The company's long-term positioning, competitive landscape, and product portfolio are also discussed for the benefit of long-term oriented investors.
Halozyme signs collaboration deal with GSK for oncology targets
Halozyme Therapeutics has entered into a global collaboration and license agreement with GSK to develop subcutaneous formulations of multiple oncology targets, including antibody drug conjugates, using Halozyme's ENHANZE drug delivery technology. The deal involves an upfront payment, potential future milestone payments, and royalties for Halozyme, with the first clinical trial projected for 2026. This collaboration marks Halozyme's first ENHANZE agreement for antibody drug conjugate targets and reflects the company's strong financial momentum and strategic efforts to expand its technology's reach.
How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data
Arcus Biosciences' Nature-published ARC-20 study data shows that casdatifan monotherapy for metastatic clear cell renal cell carcinoma links deeper HIF‑2α inhibition to changes in the biomarker serum EPO, with greater EPO suppression associated with higher response rates and longer progression‑free survival. This strengthens the biological rationale for casdatifan, potentially expanding its role in kidney cancer treatment as seen in the collaboration with Bristol Myers Squibb for the ROSETTA RCC‑208 trial. While some analysts project significant revenue and earnings growth for Arcus Biosciences, others remain more cautious, highlighting varying perspectives on the company's future investment narrative and fair value.
PFE - Pfizer Inc Volatility & Greeks
This article provides key financial data and performance metrics for Pfizer Inc. (PFE). It covers stock volatility, Greeks, trading information, insider ownership, institutional transactions, profitability ratios, and various performance indicators over different timeframes, offering a comprehensive snapshot of the company's financial health and market position.
Marie Olivier Appointed Senior Vice President, Head of Global Development Operations at Bristol Myers Squibb
Marie Olivier has been appointed as the Senior Vice President, Head of Global Development Operations (GDO) at Bristol Myers Squibb. She announced this move on LinkedIn, expressing gratitude to her former colleagues at AstraZeneca for their collaboration in accelerating clinical trials. Olivier is eager to contribute to Bristol Myers Squibb's scientific innovation and advance its pipeline to deliver innovative treatment solutions to patients globally.
BMY - Bristol-Myers Squibb Co Volatility & Greeks
This article provides detailed financial and performance data for Bristol-Myers Squibb Co (BMY), including its stock volatility, P/E ratios, dividend yield, and analyst recommendations. It also lists key financial metrics, insider and institutional ownership, and historical price performance over various periods.
If You Invested $1,000 in Cytomx Therapeutics Inc (CTMX)
This article analyzes the historical performance of a $1,000 investment in Cytomx Therapeutics Inc (CTMX) over different periods, including 1, 5, and 10 years, and since October 2015. It also provides a detailed company profile, outlining CytomX's focus on conditionally activated biologics for oncology, its proprietary PROBODY® platform, clinical pipeline, and collaborations. The data shows significant volatility and overall negative returns over longer periods, contrasting with a strong gain in the last year.
TEVA - Teva- Pharmaceutical Industries Ltd ADR Latest SEC Filings
This article provides the latest SEC filings information for Teva Pharmaceutical Industries Ltd ADR (TEVA), along with comprehensive financial data, performance metrics, and analyst ratings. It highlights the company's recent stock performance, key financial indicators like market cap and EPS, and insider/institutional ownership details.
Mesothelioma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc
DelveInsight's "Mesothelioma Pipeline Insight, 2026" report indicates that over 45 key companies are actively developing 50+ Mesothelioma treatment therapies. The report provides a comprehensive assessment of the clinical development scenario, including detailed drug descriptions, mechanisms of action, clinical studies, and regulatory approvals. Emerging therapies from companies like Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, and Pfizer are highlighted, alongside significant clinical trial developments and orphan drug designations for various treatments.
Mesothelioma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc
DelveInsight's "Mesothelioma Pipeline Insight, 2026" report provides a comprehensive overview of the global Mesothelioma treatment pipeline, identifying over 45 key companies developing more than 50 therapies. The report details clinical trial progress from pre-clinical to marketed phases, including mechanisms of action, routes of administration, and recent developments like FDA orphan drug designations and trial results for several emerging therapies. Key companies like Bristol-Myers Squibb, AstraZeneca, and Vivace Therapeutics are highlighted for their contributions to the pipeline, which includes immunotherapies, targeted therapies, and CAR-T cell treatments.
How Investors Are Reacting To Arcus Biosciences (RCUS) Nature‑Published ARC‑20 Kidney Cancer Biomarker Data
Arcus Biosciences' recently published ARC-20 study data in Nature shows a link between deeper HIF‑2α inhibition and changes in serum EPO, indicating a higher response rate and longer progression-free survival for casdatifan monotherapy in kidney cancer. This strengthens the biological rationale for casdatifan and impacts Arcus Biosciences' investment narrative, although regulatory and execution risks for its clinical pipeline remain. The company's future treatment settings and financial forecasts are closely tied to successful clinical readouts and external collaborations.
Amgen Inc. $AMGN Shares Sold by Peregrine Asset Advisers Inc.
Peregrine Asset Advisers Inc. significantly reduced its stake in Amgen (NASDAQ:AMGN) by 82.1% in the first quarter, now holding 2,801 shares valued at $986,000. Amgen is navigating mixed challenges, including a favorable ruling against a drug price cap for Enbrel but also facing scrutiny after a medical journal retracted a pivotal paper for Tavneos. Despite these, the company reported strong Q1 earnings and continues to have a robust pipeline, leading analysts to maintain a "Hold" rating with a consensus target price of $355.50.
Revolution Medicines (RVMD) Reports Phase 1 2 Pancreatic Cancer Data That Sets Up Phase 3
Revolution Medicines (RVMD) has reported promising Phase 1/2 trial data for its RAS(ON) inhibitor combinations, zoldonrasib and daraxonrasib, in metastatic pancreatic cancer. The data showed strong antitumor activity and manageable safety, particularly in patients with RAS G12D mutation, positioning the company for pivotal Phase 3 trials in both first-line and previously treated settings. These results are significant given the current lack of approved targeted options for this mutation in pancreatic cancer.
BMY’s Shift Into Russell Value Defensive Indexes Might Change The Case For Investing In Bristol-Myers Squibb (BMY)
Bristol-Myers Squibb (BMY) was reclassified into Russell's Value Defensive and Defensive Indexes in late June 2026, moving out of growth benchmarks. This change could impact how index-linked and style-focused funds hold BMY, potentially shifting its investor base and peer comparisons. While this reclassification mainly affects fund ownership rather than the underlying business, it may heighten focus on BMY's exposure to US drug pricing reforms, particularly Medicare Drug Price Negotiation Program.
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Bristol Myers Squibb Co. (BMY) shares rose by 4.16% on Thursday, closing at $58.13, contradicting a mixed trading session where the S&P 500 remained flat and the Dow Jones Industrial Average increased. This gain ended a two-day losing streak for the company's stock.
PureTech Founded Entity Celea Therapeutics Completes $180 Million Financing to Advance Deupirfenidone as a Potential New Standard of Care to Treat Idiopathic Pulmonary Fibrosis (IPF)
PureTech Health announced that its Founded Entity Celea Therapeutics has completed a $180 million financing round with participation from top-tier healthcare investors, including RA Capital Management and Leaps by Bayer. This funding will enable Celea to initiate the Phase 3 SURPASS-IPF trial for deupirfenidone (LYT-100), aiming to establish it as a new standard of care for Idiopathic Pulmonary Fibrosis (IPF). PureTech will retain a significant ownership stake of 35.4% in Celea and is eligible for substantial royalties and milestone payments, reflecting its strategy of advancing programs to value-inflection points and creating independent entities with external capital.
Bristol-Myers Squibb Hires Lobbyist on Drug Pricing
Bristol-Myers Squibb has hired Alexander J. Beckles LLC to lobby on health policy matters, specifically drug pricing, amidst increasing scrutiny and public criticism over its pricing practices, including a 4% price hike on its cancer drug Opdivo. The pharmaceutical company's move signals an intent to directly engage with Congress to influence the conversation around pharmaceutical industry regulations. This decision comes as the company, and others in the industry, navigate new "Most Favored Nation" deals with the Trump Administration.
USS Investment Management Ltd Buys 20,383 Shares of Bristol Myers Squibb Company $BMY
USS Investment Management Ltd increased its stake in Bristol Myers Squibb by 5.6% during the first quarter, purchasing an additional 20,383 shares. The firm now holds 382,894 shares valued at $23.2 million. Despite mixed Wall Street sentiment with a "Hold" consensus, Bristol Myers Squibb reported strong quarterly results, beating earnings and revenue estimates, and announced a quarterly dividend of $0.63 per share.
TAK - Takeda Pharmaceutical Co ADR Options
This article provides a detailed financial overview of Takeda Pharmaceutical Co ADR (TAK) options. It includes various financial metrics such as market capitalization, income, sales, dividend information, valuation ratios, EPS estimates, and performance statistics. The data encompasses insider and institutional ownership, profitability margins, and stock performance over different periods.
Blenrep assigned permanent billing code, supporting timely access for patients with relapsed/refractory multiple myeloma
GSK announced that Blenrep (belantamab mafodotin-blmf) has been assigned a permanent HCPCS J-code (J9053) by CMS, effective July 1, 2026. This J-code will streamline reimbursement processes for healthcare providers treating multiple myeloma patients, particularly in community oncology settings where most patients receive care. Blenrep was approved by the US FDA in October 2025 for relapsed or refractory multiple myeloma and is administered in REMS-certified outpatient settings.
ALKS - Alkermes plc Options
This article provides a detailed financial overview of Alkermes plc (ALKS), including its last close price, various financial metrics such as market cap, P/E ratio, sales, and employee count. It also lists performance indicators like volatility, RSI, and analyst recommendations, alongside insider and institutional ownership data.
Harrow Announces Commercial Launch of BYOOVIZ® in the United States
Harrow, Inc. has launched BYOOVIZ® (ranibizumab-nuna) in the United States, an FDA-approved interchangeable biosimilar to LUCENTIS, developed by Samsung Bioepis. This launch expands Harrow's retina portfolio for treating conditions like Age-Related Macular Degeneration (AMD) and Macular Edema. The company aims to provide more treatment options and economic value for retina specialists, reinforcing its presence in the growing $9 billion U.S. anti-VEGF market.
Alexandria Real Estate Equities, Inc. Releases 2025 Corporate Responsibility Report Highlighting Strategic Integration of Mission, Innovation and Long-Term Value Creation
Alexandria Real Estate Equities, Inc. (ARE) has released its 2025 Corporate Responsibility Report, detailing its integrated approach to advancing human health and innovation within the life science industry. The report highlights the company's commitment to strategic value creation through its Megacampus™ ecosystems, fostering collaboration and supporting the development of life-changing therapies. Key accomplishments include being recognized as a trustworthy and charitable company, receiving awards for industry impact, and significant reductions in operational greenhouse gas emissions.
Genmab and AbbVie’s Epkinly combo improves PFS in second-line DLBCL trial
Genmab and AbbVie have announced positive topline results from their Phase III EPCORE DLBCL-4 trial, showing that Epkinly in combination with Revlimid significantly improved progression-free survival in adult patients with relapsed or refractory diffuse large B-cell lymphoma. This success is particularly notable following a previous negative readout for overall survival in a different trial and reinforces Epkinly's potential as a core therapy for B-cell malignancies. The data will be submitted to regulatory authorities and for presentation at a future medical meeting.
Bristol-Myers Squibb Company Contingent Value Rights 2019-31.12.2030 Financial Disclosures & SEC Filings
This article provides access to the latest SEC filings and company documents for Bristol-Myers Squibb Company Contingent Value Rights (CELG/R). It lists various corporate events, earnings reports, and conference transcripts from 2025 and 2026, offering insights into the company's financial performance, operational updates, and pipeline advancements. The disclosures cover important aspects like growth portfolios, strategic initiatives, and future guidance for investors.
Alexandria Real Estate Equities, Inc. Releases 2025 Corporate Responsibility Report Highlighting Strategic Integration of Mission, Innovation and Long-Term Value Creation
Alexandria Real Estate Equities, Inc. (ARE) has released its 2025 Corporate Responsibility Report, detailing its integrated approach to advancing human health, fostering innovation, and creating long-term value. The report highlights the company's Megacampus™ ecosystems, its commitment to sustainability, and numerous accolades received for trustworthiness, charitable contributions, and leadership in the life science industry. ARE emphasizes that corporate responsibility is central to its business strategy, supporting operational excellence and delivering value for stakeholders.
Bristol-Myers Squibb Company Contingent Value Rights 2019-31.12.2030 Financial Disclosures & SEC Filings
This article provides a comprehensive list of SEC filings and company documents for Bristol-Myers Squibb Company's Contingent Value Rights. It details various corporate events, earnings reports, and conference transcripts from 2024 to 2026, offering insights into the company's financial performance, pipeline advancements, and strategic initiatives. The documents cover a range of financial disclosures, including 10-K, 10-Q, and 8-K forms, alongside investor presentations.
EXCLUSIVE: US House committee opens investigation into Merck, AbbVie China drug trials
A U.S. House Select Committee has launched national security investigations into five drugmakers, including Merck and AbbVie, over their involvement in clinical trials in China. The committee seeks details by July 17 regarding trials conducted in Xinjiang and military hospitals, citing concerns that these activities could aid China's military capabilities and expose American companies to ethical and security risks. This move reflects growing U.S. government concerns over China's expanding role in the biotech industry and its potential implications for national security.
4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
4D Molecular Therapeutics (4DMT) announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists (ASRS) in Montreal, Canada, from July 15-18, 2026. The presentation will provide a 2-year follow-up on the PRISM Phase 2b clinical trial evaluating investigational 4D-150, an intravitreal gene therapy, for neovascular AMD. 4DMT is a late-stage biotechnology company developing durable and disease-targeted therapeutics, with 4D-150 being a lead product candidate for retinal vascular diseases.
5 Best Up and Coming Pharmaceutical Stocks to Buy Now
This article identifies Alto Neuroscience, Inc. (NYSE:ANRO) as one of the top up-and-coming pharmaceutical stocks. The company recently highlighted the publication of positive results from an independent study on pramipexole for mood disorders in Nature Medicine, showing significant reduction in anhedonia. Additionally, Alto Neuroscience appointed Andrew Miller, a veteran in neuropsychiatric drug development, to its Board of Directors to aid in advancing its precision psychiatry pipeline.
Merck, AbbVie probed by US lawmakers over China clinical trials: report
A bipartisan group of U.S. lawmakers is investigating five major pharmaceutical companies, including Merck and AbbVie, regarding their clinical trials in China. The inquiry aims to determine if these trials supported China's military capabilities and if companies maintained adequate data protection. Lawmakers are requesting detailed information from the drugmakers by July 17.
Beeline ups its Series A round for immune drug work
Beeline Medicines has raised an additional $126.3 million in its Series A extension, bringing its total funding to $426.3 million. This significant investment will be used to advance the company's portfolio of Bristol Myers Squibb-licensed drugs for immune conditions, including afimetoran for systemic lupus erythematosus, which is currently in mid-stage testing. Investors, including Bain Capital and Bristol Myers, are showing strong conviction ahead of a data readout for afimetoran, highlighting a strategy of funding biotechs built around advanced experimental drugs.
Is Bristol-Myers Squibb Company (BMY) Stock at Risk From Proposed Medicare Drug Price Negotiation Updates?
Bristol-Myers Squibb Company (BMY) stock faces potential risks from proposed updates to the Medicare Drug Price Negotiation Program, which could become permanent and introduce stricter requirements for fixed-combination lifecycle strategies. However, analysts suggest that legal challenges, regulatory exemptions, and diversified product portfolios might mitigate the impact. Separately, the FDA accepted BMY's application for Camzyos for adolescents with symptomatic obstructive hypertrophic cardiomyopathy, granting it Priority Review status and setting a PDUFA action date of September 30, 2026.
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Genmab announced positive topline results from its Phase 3 EPCORE DLBCL-4 trial, showing that epcoritamab combined with lenalidomide significantly improved progression-free survival in patients with relapsed/refractory diffuse large B-cell lymphoma. The combination reduced the risk of disease progression and death by 60% and 56% respectively, with a safety profile consistent with the individual agents. Genmab and AbbVie plan to engage regulatory authorities and present these data at an upcoming medical meeting, reinforcing epcoritamab's potential as a core therapy in B-cell malignancies.
8-Day Rally Sends Revolution Medicines Stock Up 23%
Revolution Medicines (RVMD) stock has experienced an 8-day winning streak, resulting in a cumulative gain of 23% and a market cap increase of $7.1 billion, now standing at $38 billion. The article highlights RVMD's significant outperformance compared to the S&P 500 across various periods. Despite this momentum, it also cautions about the risk of single-stock investing without thorough analysis and promotes the Trefis High Quality Portfolio as a benchmark-outperforming alternative.
Drugmakers asked to defend Chinese trials; reports
The US House China Select Committee has launched an investigation into major pharmaceutical companies, including MSD, AbbVie, and Bristol Myers Squibb, regarding their use of clinical trial sites in China. The committee is scrutinizing whether trials are linked to the Chinese military or conducted in Xinjiang, raising concerns about voluntary and informed consent, as well as ethical and security risks. This move is part of a broader US effort to safeguard its biopharma interests and counter China's growing influence in drug development.
U.S. Renal Care and Akebia Announce Interim Analysis of VOICE Trial Demonstrated Overwhelming Statistical Evidence of Improved Safety Outcomes for Patients Treated with Vafseo versus an ESA
U.S. Renal Care and Akebia Therapeutics announced an interim analysis of the VOICE trial for Vafseo (vadadustat) in patients with anemia due to chronic kidney disease on dialysis. The trial was stopped early due to overwhelming statistical evidence of improved safety outcomes, specifically a significant reduction in hospitalizations for patients treated with Vafseo compared to erythropoiesis-stimulating agents (ESAs). The companies plan to present the full data at an upcoming scientific meeting, highlighting Vafseo's potential clinical benefits.
EGFR-NSCLC Market Unlocking New Revenue Opportunities and Strategic Expansion by 2036 – DelveInsight | Dizal Pharma, Eli Lilly, Cullinan Oncology, Taiho Pharma, AstraZeneca, J&J Innovative Medicine
The EGFR-NSCLC market is projected to grow significantly, from USD 7.0 billion in 2025 to USD 16.0 billion by 2036, driven by targeted therapies and advancements in treatment. Key companies like AstraZeneca, J&J, and others are actively developing and launching therapies such as amivantamab and osimertinib, which are expected to generate the highest revenues. The report highlights emerging therapies, increasing biomarker testing, and a rich pipeline as market drivers, while cost-effectiveness and small patient populations pose potential barriers.
BMS-backed Beeline 'putting worker bee mentality into effect' with $126M series A extension
Beeline Medicines, a company launched with five autoimmune programs from Bristol Myers Squibb, has secured an additional $126.3 million in a Series A extension round from existing investors including Bain Capital, Canada Pension Plan Investment Board, and BMS. This funding boosts its initial $300 million and will support ongoing trials for its lead asset, afimetoran for lupus, and other programs, with Phase 2 data expected later this year. CEO Saqib Islam emphasized the company's "worker bee mentality" and its strategy to avoid early partnerships, aiming to become a leading player in immunology and inflammation.
Lansforsakringar Fondforvaltning AB publ Has $39.97 Million Stake in Bristol Myers Squibb Company $BMY
Lansforsakringar Fondforvaltning AB publ reduced its stake in Bristol Myers Squibb (NYSE:BMY) by 13.7% in the first quarter, now holding 659,076 shares valued at $39.97 million. Despite this, institutional investors still own 76.41% of the stock, and the company recently surpassed Q1 earnings and revenue estimates while offering a 4.3% dividend yield. Analysts currently hold a consensus "Hold" rating for the biopharmaceutical company.
Pictet Asset Management Holding SA Sells 73,242 Shares of Bristol Myers Squibb Company $BMY
Pictet Asset Management Holding SA reduced its stake in Bristol Myers Squibb Company by 4.9% in the first quarter, selling 73,242 shares. Despite the sell-off, Bristol Myers Squibb reported strong first-quarter earnings, exceeding analyst expectations for both EPS and revenue, and declared a quarterly dividend of $0.63 per share.
Price to book forward of Bristol-Myers Squibb Company – LSIN:0R1F
This article provides financial data for Bristol-Myers Squibb Company (LSIN:0R1F) on the London Stock Exchange, specifically focusing on its period value, change, and change percentage in "Price to book forward." The content is presented by TradingView, detailing market data and stock information for the pharmaceutical company.
Price to book forward of Bristol-Myers Squibb Company – NYSE:BMY
This page displays the "Price to book forward" financial metric for Bristol-Myers Squibb Company (NYSE: BMY). It indicates that the market is currently closed, showing no trades. The core information presented is a financial data point for the company.
